The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Biomarker; Pharmacodynamics
- Acronyms WELCOME
- 31 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 31 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 22 Apr 2016 Results published in the Diabetologia